Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics

30-Jan-2009 - Denmark

Dako has entered into a collaboration with OSI Pharmaceuticals, Inc. Under the terms of agreement, Dako and OSI Pharmaceuticals, Inc. will collaborate on developing a new cancer diagnostic test as a potential companion product for a cancer therapy.

The new cancer diagnostic test is intended to identify patients more likely to benefit from a specific treatment. The collaboration will draw on Dako's extensive experience within the development of cancer diagnostic tests and OSI Pharmaceuticals' thorough knowledge in developing and commercializing novel pharmaceutical products.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content